JPWO2020070303A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020070303A5 JPWO2020070303A5 JP2021518493A JP2021518493A JPWO2020070303A5 JP WO2020070303 A5 JPWO2020070303 A5 JP WO2020070303A5 JP 2021518493 A JP2021518493 A JP 2021518493A JP 2021518493 A JP2021518493 A JP 2021518493A JP WO2020070303 A5 JPWO2020070303 A5 JP WO2020070303A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- mva
- administered
- taa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 claims description 53
- 230000003042 antagnostic Effects 0.000 claims description 42
- 239000005557 antagonist Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 29
- 206010025650 Malignant melanoma Diseases 0.000 claims description 28
- 201000001441 melanoma Diseases 0.000 claims description 28
- 108090001123 antibodies Proteins 0.000 claims description 25
- 102000004965 antibodies Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 108010029697 CD40 Ligand Proteins 0.000 claims description 16
- 102100003729 CD40LG Human genes 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007172 antigens Proteins 0.000 claims description 16
- 102000038129 antigens Human genes 0.000 claims description 16
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 101700025368 ERBB2 Proteins 0.000 claims description 15
- 210000004027 cells Anatomy 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 15
- 101710004105 DCT Proteins 0.000 claims description 13
- 102100007097 DCT Human genes 0.000 claims description 13
- 102100016662 ERBB2 Human genes 0.000 claims description 13
- 102100007290 CD274 Human genes 0.000 claims description 11
- 101710012053 CD274 Proteins 0.000 claims description 11
- 238000002648 combination therapy Methods 0.000 claims description 11
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 10
- 230000004083 survival Effects 0.000 claims description 10
- 201000011231 colorectal cancer Diseases 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 230000001965 increased Effects 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010017758 Gastric cancer Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 108060006580 PRAME Proteins 0.000 claims description 5
- 102100006759 PRAME Human genes 0.000 claims description 5
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000007089 Vaccinia Diseases 0.000 claims description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 230000002147 killing Effects 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000005161 thyroid carcinoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 210000004693 NK cell Anatomy 0.000 claims 2
- 230000001177 retroviral Effects 0.000 claims 2
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 102100011842 CEACAM5 Human genes 0.000 description 12
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 12
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- 102100019144 CD46 Human genes 0.000 description 9
- 102100005310 CTLA4 Human genes 0.000 description 9
- 101700054183 CTLA4 Proteins 0.000 description 9
- 101710004393 HAVCR2 Proteins 0.000 description 9
- 102100016384 HAVCR2 Human genes 0.000 description 9
- 108060004270 LAG3 Proteins 0.000 description 9
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 9
- 102100013504 RPL17 Human genes 0.000 description 9
- 108060007796 SPATA2 Proteins 0.000 description 9
- 102100003649 ACP3 Human genes 0.000 description 6
- 102100008450 AFP Human genes 0.000 description 6
- 102100008990 CASP8 Human genes 0.000 description 6
- 101700020617 CD22 Proteins 0.000 description 6
- 102100000189 CD22 Human genes 0.000 description 6
- 101700078950 CD44 Proteins 0.000 description 6
- 102100003735 CD44 Human genes 0.000 description 6
- 108010009575 CD55 Antigens Proteins 0.000 description 6
- 102100003281 CD59 Human genes 0.000 description 6
- 108090000538 Caspase 8 Proteins 0.000 description 6
- 102000011412 Complement 3d Receptors Human genes 0.000 description 6
- 108010023729 Complement 3d Receptors Proteins 0.000 description 6
- -1 Dna78 Proteins 0.000 description 6
- 101700053597 FCER2 Proteins 0.000 description 6
- 102100014608 FCER2 Human genes 0.000 description 6
- 101700036477 FOLH1 Proteins 0.000 description 6
- 102100008453 FOLH1 Human genes 0.000 description 6
- 102000005720 Glutathione Transferase family Human genes 0.000 description 6
- 108010070675 Glutathione Transferase family Proteins 0.000 description 6
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 6
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 6
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 description 6
- 241000681881 Human mammary tumor virus Species 0.000 description 6
- 102100015968 IL4R Human genes 0.000 description 6
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 6
- 102100013180 KDR Human genes 0.000 description 6
- 101710030888 KDR Proteins 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 102100017213 LAG3 Human genes 0.000 description 6
- 102100008857 MLANA Human genes 0.000 description 6
- 102100006037 MUC1 Human genes 0.000 description 6
- 101700052761 MUC1 Proteins 0.000 description 6
- 108010005662 Membrane Cofactor Protein Proteins 0.000 description 6
- 102100005499 PTPRC Human genes 0.000 description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 101700038204 TGFA Proteins 0.000 description 6
- 102100014223 TGFA Human genes 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 6
- 101700034648 fgf8b Proteins 0.000 description 6
- 150000002270 gangliosides Chemical class 0.000 description 6
- 102000035501 human TERT protein Human genes 0.000 description 6
- 108091005810 human TERT protein Proteins 0.000 description 6
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 6
- 210000001744 T-Lymphocytes Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102100014001 ABCB1 Human genes 0.000 description 3
- 101700029306 ANG1 Proteins 0.000 description 3
- 102100006414 AZGP1 Human genes 0.000 description 3
- 101710008966 AZGP1 Proteins 0.000 description 3
- 108010002367 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 3
- 101710043900 At2g44920 Proteins 0.000 description 3
- 102000015600 B melanoma antigen Human genes 0.000 description 3
- 108050004877 B melanoma antigen Proteins 0.000 description 3
- 102100007326 BIRC5 Human genes 0.000 description 3
- 102100001537 CA9 Human genes 0.000 description 3
- 101710040946 CA9 Proteins 0.000 description 3
- 101700087100 CD19 Proteins 0.000 description 3
- 102100005826 CD19 Human genes 0.000 description 3
- 102100016493 CD33 Human genes 0.000 description 3
- 101700017647 CD33 Proteins 0.000 description 3
- 101710027020 CD46 Proteins 0.000 description 3
- 102100019283 CD52 Human genes 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 102100013391 CD55 Human genes 0.000 description 3
- 101710006195 CD55 Proteins 0.000 description 3
- 101700073334 CD59 Proteins 0.000 description 3
- 108010055167 CD59 Antigens Proteins 0.000 description 3
- 102100013075 CDC27 Human genes 0.000 description 3
- 102100019398 CDK4 Human genes 0.000 description 3
- 101700008359 CDK4 Proteins 0.000 description 3
- 102100005552 CR1 Human genes 0.000 description 3
- 101700042195 CR1 Proteins 0.000 description 3
- 102100009368 CR2 Human genes 0.000 description 3
- 101700020447 CR2 Proteins 0.000 description 3
- 102100001891 CTAG1A Human genes 0.000 description 3
- 101710004449 CTAG1A Proteins 0.000 description 3
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 3
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 3
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 101700086219 DVA-1 Proteins 0.000 description 3
- 102100009914 EBAG9 Human genes 0.000 description 3
- 101710010062 EBAG9 Proteins 0.000 description 3
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 3
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 3
- 101710038745 EEF1A2 Proteins 0.000 description 3
- 102400000102 Eosinophil granule major basic protein Human genes 0.000 description 3
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 3
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 3
- 102000006815 Folate receptors Human genes 0.000 description 3
- 108020005243 Folate receptors Proteins 0.000 description 3
- 102000020337 GAGE family Human genes 0.000 description 3
- 108091015116 GAGE family Proteins 0.000 description 3
- 102100001448 GAST Human genes 0.000 description 3
- 101700005903 GAST Proteins 0.000 description 3
- 102400000921 Gastrin Human genes 0.000 description 3
- 102100003684 HPSE Human genes 0.000 description 3
- 101700071120 HSTN Proteins 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108050003490 Insulin-like growth factor Proteins 0.000 description 3
- 102000014429 Insulin-like growth factor Human genes 0.000 description 3
- 101700033678 KDR Proteins 0.000 description 3
- 101710033922 KRAS Proteins 0.000 description 3
- 101710025361 LPGAT1 Proteins 0.000 description 3
- 102100018587 LPGAT1 Human genes 0.000 description 3
- GKDWRERMBNGKCZ-RNXBIMIWSA-N Little gastrin I Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 3
- 108010010995 MART-1 Antigen Proteins 0.000 description 3
- 102100011874 MELTF Human genes 0.000 description 3
- 101710042280 MELTF Proteins 0.000 description 3
- 101710012533 MLANA Proteins 0.000 description 3
- 101700007600 MOK Proteins 0.000 description 3
- 102100018023 MOK Human genes 0.000 description 3
- 101710005599 MRPL28 Proteins 0.000 description 3
- 102100000165 MS4A1 Human genes 0.000 description 3
- 101710010909 MS4A1 Proteins 0.000 description 3
- 101710034449 MT-CO2 Proteins 0.000 description 3
- 102100006044 MUC16 Human genes 0.000 description 3
- 102100015262 MYC Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 101710043884 Mup15 Proteins 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 101700049309 NOS2 Proteins 0.000 description 3
- 102100002496 NOS2 Human genes 0.000 description 3
- 101710033916 NRAS Proteins 0.000 description 3
- 102100001119 NRAS Human genes 0.000 description 3
- 101700042042 NXT1 Proteins 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 101710003000 ORF1/ORF2 Proteins 0.000 description 3
- 101700045069 ORF4 Proteins 0.000 description 3
- 102000009890 Osteonectin Human genes 0.000 description 3
- 108010077077 Osteonectin Proteins 0.000 description 3
- 101710043203 P23p89 Proteins 0.000 description 3
- 102100004854 PDZK1IP1 Human genes 0.000 description 3
- 101710008157 PDZK1IP1 Proteins 0.000 description 3
- 102100015381 PTGS2 Human genes 0.000 description 3
- 101710040930 PTGS2 Proteins 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 3
- 101700044827 RNMT Proteins 0.000 description 3
- 102100004228 SART1 Human genes 0.000 description 3
- 101710037092 SART1 Proteins 0.000 description 3
- 101710040834 SSO0094 Proteins 0.000 description 3
- 102000035572 SSX family Human genes 0.000 description 3
- 108091018015 SSX family Proteins 0.000 description 3
- 102100019667 STAT3 Human genes 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- 102100017517 SUB1 Human genes 0.000 description 3
- 101700063611 SUB1 Proteins 0.000 description 3
- 108010002687 Survivin Proteins 0.000 description 3
- 102100009560 TNFRSF6B Human genes 0.000 description 3
- 101710022317 TNFRSF6B Proteins 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- LFTYTUAZOPRMMI-CFRASDGPSA-L UDP-N-acetyl-α-D-glucosamine(2-) Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP([O-])(=O)OP([O-])(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-L 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 101710025562 alphaTub85E Proteins 0.000 description 3
- 102000015735 beta Catenin Human genes 0.000 description 3
- 108060000903 beta Catenin Proteins 0.000 description 3
- 102000006834 complement receptors Human genes 0.000 description 3
- 108010047295 complement receptors Proteins 0.000 description 3
- 108060003523 dnaK Proteins 0.000 description 3
- 101700013556 entH Proteins 0.000 description 3
- 108010048134 estramustine-binding protein Proteins 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 108010066264 gastrin 17 Proteins 0.000 description 3
- 101710031154 gene 11 Proteins 0.000 description 3
- 101710017840 gene 15 Proteins 0.000 description 3
- 101700051903 gph1 Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 108010037536 heparanase Proteins 0.000 description 3
- 101710030893 kdrl Proteins 0.000 description 3
- 108090000015 mesothelin Proteins 0.000 description 3
- 102000003735 mesothelin Human genes 0.000 description 3
- 108010042121 probasin Proteins 0.000 description 3
- 239000003488 releasing hormone Substances 0.000 description 3
- 229960005486 vaccines Drugs 0.000 description 3
- 102000027760 ERBB2 Human genes 0.000 description 2
- 229940022353 Herceptin Drugs 0.000 description 2
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 2
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 1
- 102100005376 BMP2K Human genes 0.000 description 1
- 101700041449 BMP2K Proteins 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- 102100010782 EGFR Human genes 0.000 description 1
- 101700039191 EGFR Proteins 0.000 description 1
- 102000009071 ErbB Receptors Human genes 0.000 description 1
- 108010073043 ErbB Receptors Proteins 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 101700055706 LITAF Proteins 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101700022528 TBX1 Proteins 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000020127 ayran Nutrition 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18199002.9 | 2018-10-05 | ||
| EP18199002 | 2018-10-05 | ||
| PCT/EP2019/076947 WO2020070303A1 (fr) | 2018-10-05 | 2019-10-04 | Polythérapie pour le traitement du cancer comprenant une administration intraveineuse de mva recombiné et d'un antagoniste ou d'un agoniste d'un point de contrôle immunitaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512595A JP2022512595A (ja) | 2022-02-07 |
| JPWO2020070303A5 true JPWO2020070303A5 (fr) | 2022-09-26 |
Family
ID=63998486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518493A Pending JP2022512595A (ja) | 2018-10-05 | 2019-10-04 | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3860641A1 (fr) |
| JP (1) | JP2022512595A (fr) |
| AU (1) | AU2019354101A1 (fr) |
| CA (1) | CA3113818A1 (fr) |
| IL (1) | IL281988A (fr) |
| WO (1) | WO2020070303A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP4061405A1 (fr) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations |
| WO2022036495A1 (fr) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| EP0247091B1 (fr) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0768377A1 (fr) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Production et sélection de protéines de liaison diversifiées de recombinaison |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| CA2108147C (fr) | 1991-04-10 | 2009-01-06 | Angray Kang | Banques de recepteurs heterodimeriques construites a l'aide de phagemides |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| MXPA01003503A (es) | 1998-10-05 | 2005-01-14 | Pharmexa As | Nuevos metodos terapeuticos de vacunacion. |
| DE60116371T3 (de) | 2000-11-23 | 2016-11-17 | Bavarian Nordic A/S | Variante des modifizierten vaccinia ankara virus |
| WO2003047506A2 (fr) | 2001-11-30 | 2003-06-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptides agonistes d'antigenes specifiques de la prostate et leurs utilisations |
| AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| JP2012509678A (ja) | 2008-11-27 | 2012-04-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組換えウイルス発現のためのプロモーター |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| WO2011041613A2 (fr) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Immunothérapie combinée pour le traitement du cancer |
| SG193428A1 (en) | 2011-03-31 | 2013-10-30 | Inst Nat Sante Rech Med | Antibodies directed against icos and uses thereof |
| WO2013103658A1 (fr) | 2012-01-03 | 2013-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Épitopes de ctl endogènes et agonistes de l'antigène tumoral muc1 |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014037124A1 (fr) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Procédés et compositions pour l'amélioration de réponses immunitaires à la vaccine |
| WO2014043535A1 (fr) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions destinées à traiter le cancer |
| WO2014062778A1 (fr) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Méthodes et compositions pour le traitement du cancer |
| EP3778904A1 (fr) | 2012-10-28 | 2021-02-17 | Bavarian Nordic A/S | Promoteur pr13.5 pour lymphocytes t robustes et réponses d'anticorps |
| KR102395820B1 (ko) * | 2013-11-05 | 2022-05-09 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제 |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| EP3256156A1 (fr) * | 2015-02-13 | 2017-12-20 | Transgene SA | Vaccin immunothérapeutique et thérapie combinée à base d'anticorps |
| CA2990549A1 (fr) | 2015-07-31 | 2017-02-09 | Bavarian Nordic A/S | Promoteurs pour ameliorer l'expression dans les virus du groupe pox |
-
2019
- 2019-10-04 AU AU2019354101A patent/AU2019354101A1/en active Pending
- 2019-10-04 EP EP19780255.6A patent/EP3860641A1/fr active Pending
- 2019-10-04 JP JP2021518493A patent/JP2022512595A/ja active Pending
- 2019-10-04 WO PCT/EP2019/076947 patent/WO2020070303A1/fr active Application Filing
- 2019-10-04 CA CA3113818A patent/CA3113818A1/fr active Pending
-
2021
- 2021-04-01 IL IL281988A patent/IL281988A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7368305B2 (ja) | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 | |
| JP2023030083A (ja) | 治療用ｒｎａ | |
| US20200085891A1 (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| AU2017274540B2 (en) | Compositions and methods for tumor vaccination using prostate cancer-associated antigens | |
| US20190134174A1 (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
| JP2016512199A (ja) | 腫瘍溶解性ウイルス | |
| JP2017515841A5 (fr) | ||
| US11723964B2 (en) | Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA | |
| JP2022507744A (ja) | ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法 | |
| JP2020531524A5 (fr) | ||
| Radosa et al. | Clinical data on immunotherapy in breast cancer | |
| Harrop et al. | Viral vectors for cancer immunotherapy | |
| Li et al. | Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review | |
| JPWO2020070303A5 (fr) | ||
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| Izzi et al. | Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains | |
| US20230190922A1 (en) | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer | |
| WO2021150713A2 (fr) | Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e | |
| US20230277592A1 (en) | Armed Dual CAR-T Compositions and Methods For Cancer Immunotherapy | |
| RU2795103C2 (ru) | Комбинированная терапия для лечения рака путем внутривенного введения рекомбинантного mva и антитела | |
| CA3240596A1 (fr) | Therapie pour moduler une reponse immunitaire au moyen d'un mva recombinant codant pour il-12 | |
| US20240252563A1 (en) | Cancer treatments | |
| WO2023064793A1 (fr) | Protéines de fusion de l'interleukine 7 et de l'interleukine 21 | |
| JPWO2019038388A5 (fr) | ||
| Gomar et al. | Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI: C |